HBHayrunnisa Bekis Bozkurt

Hayrunnisa Bekis Bozkurt

*This is an algorithmically generated author record based on publicly available information.

Hayrunnisa Bekis Bozkurt has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Systematic review of hematopoietic stem cell transplantation in patients with ataxia telangiectasia: a case report and an individual patient-level analysis

    by Hayrunnisa Bekis Bozkurt, Virginia Meda Spaccamela, Moustapha Hassan, Matthias Felber, Ulrike Zeilhofer, Aida Zeckanovic, Jean-Pierre Bourquin, David Jacquier, Francesco Ceppi, Fabio Candotti, et al.

    Background: There is a lack of clinical data on hematopoietic stem cell transplantation (HSCT) in Ataxia-Telangiectasia (A-T) patients due to the underlying chromosomal instability that leads to low tolerance to chemotherapy. To effectively manage cancer and immune risks, there is a need for improved HSCT protocols, novel therapies, and long-term monitoring. This report describes a 16-year-old boy with A-T and T-ALL who achieved long-term leukemia-free survival after HSCT using a tailored, drug-monitored conditioning regimen. His results were analyzed in the context of a systematic review of the literature on HSCT outcomes in A-T patients. Methods: A thorough literature review was conducted using a comprehensive search of the PubMed, Scopus, and Google Scholar databases. The search was limited to studies published between September 1, 2000, and September 1, 2025. Eligible studies were required to involve human participants and to include at least one patient with a confirmed diagnosis of A-T, with transplantation interventions. Results: The analysis included 16 A-T patients, including our patient, who underwent HSCT. The median age at transplantation was 48 months (interquartile range [IQR]: 22–142 months). Myeloablative conditioning (MAC) was administered to two patients, both of whom died. Reduced-intensity conditioning (RIC) was utilized for nine patients, with three deaths (33.3%). Reduced-toxicity conditioning (RTC) was administered in two patients, with one patient experiencing a fatal outcome. In total, eight patients (50%) experienced significant drug-related toxicities, eight (50%) had GvHD and only eight patients (50%) survived. Our patient underwent HSCT of a matched sibling donor after administration of adjusted treosulfan doses (cumulative AUC of 4671 mg/Lxh), and achieved leukemia-free survival with complete hematological and normalized thymic function without graft-versus-host disease (GvHD). Conclusion: Despite the historically poor survival outcomes observed in transplanted A-T patients, new HSCT strategies, such as treosulfan therapeutic drug monitoring and personalized drug profiles to select potent but less toxic agents, warrant reevaluation to achieve durable remission in leukemia and lymphoma. These findings underscore the necessity to persist in the development of innovative HSCT approaches with the objective of expanding therapeutic options for both malignancies and combined immunodeficiency.

  • Open Access

    A Survey on Environmental Protective and Risk Factors and Awareness Related to Epithelial Barrier Integrity, Microbiome and Allergic Diseases

    by Arzu Bakirtas, Ayca Kiykim, A. Kubra Baskin, Hulya Anil, Hayrunnisa Bekis Bozkurt, Sevgi Sipahi Cimen, Zeynep Hizli Demirkale, Saliha Esenboga, Ismail Ogulur, Sena Ardicli, et al.


  • Open Access

    Evaluating the Use of Nasal Epinephrine in Anaphylaxis: Current Status

    by Hayrunnisa Bekis Bozkurt, İlKnur Pençe

    The use of epinephrine auto-injectors is life-saving in serious allergic reactions such as out-ofhospital anaphylaxis. However, several factors limit their use, including patients not obtaining their prescriptions, the difficulty of carrying auto-injectors, and fear of injection. Administering epinephrine as early as possible to a patient experiencing anaphylaxis significantly reduces mortality and morbidity. Many experts are therefore interested in developing life-saving medical treatments in forms that are easier to access and apply. Nasal epinephrine consists of 3 components: epinephrine, a unit-dose spray, and İntravair. This spray was developed in collaboration with both the Food and Drug Administration and the European Medicines Agency. In addition to its ease of use, nasal epinephrine has shown favorable pharmacokinetic and pharmacodynamic (PD) responses for various symptoms, including allergic and infectious rhinitis. Notably, it has been found that nasal epinephrine provides a better PD response than injections; the increase in heart rate and blood pressure within 1 minute of administration confirms receptor activation in this drug’s mechanism of action. These findings indicate that nasal epinephrine could be a choice for the treatment of serious allergic reactions, including anaphylaxis, and could be safe and effective. Cite this article as: Bozkurt HB, Pen.e İ. Evaluating the use of nasal epinephrine in anaphylaxis: Current status. Turk Arch Pediatr. 2025;60(6):572-576.


  • Open Access

    Evaluation of Osteoarticular Involvement Associated with Brucellosis in Children

    by Tuğba Nur Kutlu Beşeren, Hayrunnisa Bekis Bozkurt, Müferet Ergüven, Zafer Bıçakçı

    Aim: Brucellosis is a significant public health problem with high morbidity. Its most frequent complication is osteoarticular involvement. The study aimed to evaluate the relationship of osteoarticular involvement with clinical features and prognosis in children with brucellosis. Material and Methods: This retrospective study included pediatric patients between the ages of 1 and 18 years who were hospitalized and diagnosed with brucellosis between 2015 and 2020, and were regularly followed up. and all their findings and osteoarticular involvement data within the last two years were recorded. Clinical features, laboratory findings, osteoarticular involvement, and relapse rates of the patients were evaluated. Results: A total of 80 patients were included study. During the follow-up period, relapse developed in 14 (17.5%) patients. The most commonly affected joints were right (40%, n=32) and left (26.3%, n=21) hips, then right (27.5%, n=22) and left (23.8%, n=19) knees. Shoulder joint involvement rates and C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), alanine transaminase (ALT), and aspartate aminotransferase (AST) levels were statistically significantly higher in the relapse group (p=0.016, p=0.003, p=0.001, p

  • Open Access

    Correction to: Evaluation of drug-related anaphylaxis in children: multi-center study

    by Azize Pınar Metbulut, İdIl Akay Haci, Demet Can, Hayrunnisa Bekis Bozkurt, Özlem Cavkaytar, Mustafa Arga, Deniz Özçeker, Yüksel Kavas Yildiz, Emine Vezir, Tuğba Arikoğlu, et al.


  • Evaluation of drug-related anaphylaxis in children: multi-center study

    by Azize Pınar Metbulut, İdIl Akay Haci, Demet Can, Hayrunnisa Bekis Bozkurt, Özlem Cavkaytar, Mustafa Arga, Deniz Özçeker, Yüksel Kavas Yildiz, Emine Vezir, Tuğba Arikoğlu, et al.

    The aim of the study is to elucidate demographic characteristics, risk factors, clinical presentations, causative agents, and management approaches pertaining to drug-related anaphylaxis in the paediatric population. This study is a multicenter retrospective study that included paediatric patients aged between 1 month and 18 years, who were admitted to the Pediatric Allergy and Immunology outpatient clinics of 11 participating centres with a presumptive diagnosis of drug-induced anaphylaxis, that fulfilled the standardised criteria for anaphylaxis, between January 2017 and December 2022. A total of 293 anaphylactic episodes presented among 265 patients, of which 48.1% (n 141) were female, were included. The median age of patients during the index episode was 107 months (IQR 56.5–161.5). Anaphylaxis occurred most frequently within hospital settings (62.1%, n 182) compared to home environments (34.1%, n 100). The administration were peroral in 40.3% (n 118), parenteral in 59.7% (n 175) of the cases. While antibiotics (56.7%), non-steroidal anti-inflammatory drugs (25.7%), and chemotherapeutics (3.4%) were the most commonly suspected drug groups, the cephalosporin group, and especially ceftriaxone (27.5% [n 80]) were the leading culprits among antibiotics. The anaphylaxis severity was severe in 39.6% (n 116), and moderate in 54.9% (n 161) of episodes. A biphasic reaction occurred in five patients. Only 72% (n 213) of patients were given adrenaline treatment. There were no fatalities. Diagnostic tests (n 64), including skin prick, intradermal, and drug provocation tests, which were performed between 1 and 120 months after the index reaction, yielded positive results in 23.4% (n 15), 17.2% (n 11), and 20.3% (n 13) of cases respectively, giving a total confirmation of 39 patients. Four patients underwent suspected drug desensitisation protocols. There were no fatalities. Conclusions: Antibiotics, particularly ceftriaxone, were the most commonly implicated agents in paediatric drug-induced anaphylaxis. Non-steroidal anti-inflammatory drugs, particularly ibuprofen, constituted the second most frequently implicated drug group. Paediatric patients experiencing drug-related anaphylaxis warrant algorithmic evaluation to ensure accurate diagnosis, prevent recurrence, and identify safe alternative treatments. What is Known: • Antibiotics, particularly ceftriaxone were the most frequently implicated culprit drugs, followed by NSAIDs, with ibuprofen being the most common within this group. What is New: • To the best of our knowledge, this is the largest multicenter paediatric drug-related anaphylaxis study, involving a large number of patients who evaluated by paediatric allergist. • We propose paediatric patients who experience drug induced anaphylaxis should undergo evaluation at specialized centres, to ensure accurate diagnosis, to prevent recurrence and identify safe alternative treatments.


  • Open Access

    Increasing Importance of Genotype–Phenotype Correlations Associated with Common and Rare MEFV Gene Mutations in FMF Patients in the Last Thirty Years

    by Sema Yildirim, Hayrunnisa Bekis Bozkurt, Muferet Erguven

    Background/Objectives: Studies have shown that some mutations, especially M694V, are correlated with renal RI and/or AA. There are limited data about rare mutations on severity of the disease and RI. Today, evaluating genotype–phenotype correlations in rare mutations is important to better understand FMF. We aimed to evaluate clinical, demographic and genetic changes and genotype–phenotype correlations in pediatric patients with FMF over thirty years as well as the importance of the rare mutations. Methods: A total of 2765 pediatric patients with FMF were included in this study. Genetic results were firstly divided into ten groups including rare mutations. Rare mutations were seen in 2% of all patients and divided into eight groups. Results: There was a significant increase in compound heterozygous mutations, E148Q het/hom, R202Q het/hom, complex mutations and rare mutations in the last decade. RI wo AA was 5.8% and AA was 1% in the patients with rare mutations. While M694V and compound het with M694V were positively correlated with severe PRAS, E148Q and V726A were negatively correlated with severe PRAS (p < 0.05, R = 0.137, R = −0.077, R= −0.05, respectively). Although K695R mutation was negatively correlated with severe PRAS (p < 0.05, R = −0.04), the rate of RI was 20%. Although the rare mutation R761H was negatively correlated with severe PRAS (p < 0.05, R = −0.051), the colchicine resistance rate was 8.3%. Conclusions: It may be misleading for clinicians that mutations which have increased in frequency over the years are clinically mild. RI and AA rates in rare mutations are not less than the related rates in common mutations.


  • Allergic Reactions to Vaccines: Diagnosis and Management

    by Hayrunnisa Bekis Bozkurt, Öner Özdemir

    Childhood vaccinations are the most cost-effective method to combat preventable diseases. Allergic reactions to vaccines are generally rare. However, all vaccines can potentially cause allergic reactions. These allergic reactions can develop against any of the components of the vaccine (adjuvant, microbial agent, stabilizer, residue antibiotic, cell culture, etc.). It is very important to correctly diagnose allergic reactions to vaccines because only 15% of suspected allergic reactions to vaccines are real allergic reactions and the continuation of immunization procedures is essential for public health. Allergic reactions to vaccines should be evaluated by an allergist-immunologist expert and a risk analysis should be performed. Vaccination of these children in a reliable way and guaranteed immunization procedure will also contribute to the protection of both children and public health. This study compiles the diagnosis of immediate and delayed reactions to vaccines or vaccine components and their management with current guidelines.

  • Open Access

    Bartter syndrome: A case report requiring emergency intervention

    by Hayrunnisa Bekis Bozkurt, Tuğba Nur Kutlu, Müferet Ergüven, Zafer Bıçakcı

    Bartter sendromu, hipokalemi, hipokloremik metabolik alkaloz ve hiperaldosteronizm ile hiperreninemiye rağmen normal kan basıncı ile karakterize otozomal resesif nadir bir genetik hastalıktır. Bartter sendromunun tedavisinde, dehidratasyonun giderilmesi, elektrolit dengesizliğinin düzeltilmesi, genel destek ve replasman tedavileri ile varsa eşlik eden enfeksiyonun tedavisi önceliklidir. Bu yazıda, 3 yaş 6 aylık Bartter sendromu tanısı ile takip edilen hasta, ayırıcı tanıda akılda tutulması ve farkındalığın artırılması amacıyla sunulmuştur. Bartter syndrome is a rare autosomal recessive genetic disease characterized by hypokalemia, hypochloremic metabolic alkalosis, and normal blood pressure despite hyperaldosteronism and hyperreninemia. In the treatment of Bartter syndrome, the priority is to eliminate dehydration, correct electrolyte imbalance, provide general support and replacement therapies, and treat any accompanying infection. In this article, a patient diagnosed with Bartter syndrome, aged 3 years and 6 months, was presented to highlight this condition in differential diagnosis and increase awareness.